Understanding Genetically Transitional Disease and Its Implications for Classification
The traditional binary framework dividing human diseases into strictly monogenic or polygenic categories has long guided clinical genetics and research. Monogenic conditions typically involve high-penetrance variants following clear Mendelian inheritance patterns, while polygenic diseases arise from numerous small-effect variants interacting with environmental factors. However, advances in genomic sequencing have revealed a spectrum of disorders that defy this dichotomy. Genetically transitional disease, often abbreviated as GTD, represents conditions where a specific gene mutation is necessary yet insufficient on its own to trigger full disease manifestation. This concept emphasizes variable gene penetrance, where the likelihood that a variant carrier develops the associated phenotype ranges from low to moderate rather than near-complete.
Penetrance itself refers to the proportion of individuals carrying a particular genetic variant who actually express the associated trait or disorder. In high-penetrance scenarios common to classic monogenic diseases, nearly all carriers develop symptoms. In GTD, penetrance is reduced, meaning additional genetic modifiers, environmental influences, or stochastic factors determine whether disease emerges. This nuanced understanding challenges clinicians and researchers to rethink diagnostic criteria, genetic counseling approaches, and therapeutic strategies.
The Landmark Publication Advancing Penetrance Discussions
A timely review article titled "Challenging traditional classifications: Gene penetrance in genetically transitional disease" explores these issues in depth. Authored by Peter D. Gorevic, Timothy B. Niewold, Ivona Aksentijevich, Gerald Pfeffer, Joan Guitart, Grant S. Schulert, Madhuri Hegde, Russell Bowler, Greg Gibson, and Qingping Yao, the work appears in the journal Genes & Diseases. Readers can access the full publication at https://www.sciencedirect.com/science/article/pii/S2352304226003065. The authors draw on expertise spanning rheumatology, immunology, genetics, and pulmonary medicine to illustrate how penetrance considerations reshape nosology in genomic medicine.
The paper synthesizes evidence from autoinflammatory conditions and related disorders, demonstrating that low-penetrance variants in genes such as NOD2 or NLRP family members often require secondary triggers. This framework moves beyond rigid classifications toward models that better reflect real-world clinical heterogeneity.
Historical Context and Evolution of the GTD Concept
The GTD terminology emerged from earlier foundational work proposing it as a bridge category. In a 2023 publication in Trends in Genetics, researchers defined GTD as cases where a large-effect mutation proves necessary but not sufficient for disease. Four primary scenarios were outlined: subsets of traditionally Mendelian diseases showing incomplete penetrance, modifiable Tier 1 monogenic conditions, variable expressivity in dominant disorders, and certain complex traits influenced by major-effect alleles.
Subsequent developments, including a 2025 perspective on the road to personalized medicine, expanded applications to rheumatic and autoinflammatory diseases. These publications highlight how next-generation sequencing has identified numerous variants previously dismissed as benign or of uncertain significance that actually contribute meaningfully when penetrance is considered.
Real-world examples include Yao syndrome, linked to low-penetrance NOD2 variants. Carriers may remain asymptomatic or develop periodic fever, dermatitis, and arthritis only under specific environmental or additional genetic conditions. Similar patterns appear in certain NLRP3- and NLRP12-associated autoinflammatory diseases, where clinical phenotypes overlap yet penetrance varies widely among families.
Mechanisms Underlying Variable Penetrance in GTD
Penetrance in GTD arises through multiple interacting layers. Primary variants may alter protein function modestly, requiring compound heterozygosity, digenic inheritance, or somatic second hits to reach a disease threshold. Epigenetic modifications, microbiome influences, infections, or lifestyle factors further modulate outcomes.
Step-by-step, the process often begins with identification of a candidate variant through targeted panels or whole-exome sequencing. Functional studies then assess impact on protein activity or signaling pathways, such as inflammasome activation in autoinflammatory contexts. Population studies compare allele frequencies in affected versus unaffected individuals to estimate penetrance rates. Finally, longitudinal cohort data reveal modifiers that tip the balance toward clinical expression.
This layered model explains why some families show striking intrafamilial variability despite sharing the same primary variant. It also accounts for late-onset presentations or incomplete phenotypes that traditional high-penetrance models cannot accommodate.
Photo by Abdulai Sayni on Unsplash
Clinical and Research Implications Across Disciplines
Adopting GTD frameworks carries direct consequences for patient care. Genetic testing reports may now incorporate nuanced language around low-penetrance variants instead of binary pathogenic or benign labels. Counseling shifts from definitive risk percentages toward probabilistic discussions incorporating family history, lifestyle, and potential triggers.
In research settings, GTD encourages broader phenotyping and multi-omics integration. Studies of autoinflammatory cohorts have already benefited, revealing shared pathways between conditions once viewed as distinct. Pulmonary and dermatologic manifestations, as explored by several of the current paper's authors, further illustrate cross-specialty relevance.
Stakeholder perspectives vary. Clinicians value improved diagnostic precision, while patients gain clearer expectations and access to emerging targeted therapies. Laboratory geneticists face updated variant classification guidelines that accommodate penetrance data. Public health entities consider screening implications for populations harboring common low-penetrance alleles.
Case Studies Illustrating GTD in Practice
Consider a family with recurrent fevers and elevated inflammatory markers. Initial testing identifies a heterozygous NOD2 variant previously associated with low penetrance. Under GTD classification, clinicians investigate additional factors such as concurrent infections or polygenic risk scores rather than attributing symptoms solely to the variant.
Another example involves adult-onset hearing loss linked to specific GJB2 alleles. Homozygosity for certain hypomorphic variants produces mild phenotypes with reduced penetrance compared to compound heterozygosity with null alleles. Such cases underscore the value of detailed allelic architecture analysis.
These examples demonstrate how GTD thinking prevents both overdiagnosis in asymptomatic carriers and underdiagnosis in individuals whose phenotypes result from combined influences.
Challenges in Implementation and Ongoing Debates
Despite promise, GTD adoption faces hurdles. Standardized penetrance estimation requires large, diverse cohorts often unavailable for rare variants. Environmental data collection remains inconsistent across studies. Regulatory frameworks for genetic testing and insurance coverage have yet to fully adapt to probabilistic rather than deterministic interpretations.
Debates persist around thresholds: at what penetrance level does a condition transition from monogenic to GTD? How should expressivity variability factor into classification? The current review addresses these by advocating flexible, evidence-based nosology that evolves with accumulating data.
Future Directions and Broader Impact on Genomic Medicine
Looking ahead, integration of artificial intelligence for penetrance prediction from multi-dimensional datasets holds significant potential. Polygenic risk scores combined with major-effect variants may refine individual risk profiles. Therapeutic development could target modifiable modifiers rather than the primary variant alone.
International consortia are already incorporating GTD language into disease ontologies. This shift supports precision medicine initiatives aiming to tailor interventions based on an individual's full genetic and exposome context. Educational programs in medical genetics and genomics are beginning to include GTD modules to prepare the next generation of clinicians and researchers.
The publication by Gorevic, Niewold, Aksentijevich and colleagues provides a critical synthesis that will likely influence guidelines from professional societies in the coming years. Its emphasis on penetrance as a dynamic rather than fixed property encourages ongoing reevaluation of disease boundaries.
Actionable Insights for Researchers and Clinicians
Professionals encountering suspected GTD cases should prioritize comprehensive variant interpretation including population databases and functional assays. Multidisciplinary teams facilitate holistic assessment of modifiers. Patients benefit from clear communication framing risk as modifiable rather than inevitable.
Institutions can support this paradigm through updated curricula, research funding prioritizing penetrance studies, and clinical decision-support tools incorporating GTD logic. Collaborative data sharing across borders accelerates discovery of additional examples and modifiers.
